Robotic gastrectomy using a patient-side 5th robotic arm
Official title: Robotic Gastrectomy With a Novel 5th Arm - an International Multicenter Pilot Study
Run by Chinese University of Hong Kong · NCT07310888 · Data updated 2026-11-12
This trial will try a new multiport robotic system with an extra patient-side arm for adults with operable stomach cancer to see if the surgery works well and is safe.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Drugs / interventions | Cart |
| Locations | 2 sites (Hong Kong and 1 other locations) |
| Status | Recruiting |
| Started | December 31, 2025 |
| Main results expected | December 30, 2027 |
| Study ends | January 31, 2028 |
| Registry record updated | December 30, 2025 |
| Trial ID | NCT07310888 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–75 with newly diagnosed, operable stomach or gastro-esophageal junction cancer planned for elective gastrectomy and with BMI under 35 who can give informed consent are ideal candidates.
✕Probably not a fit
Patients with prior abdominal surgery that prevents minimally invasive gastrectomy, distant metastasis or another active malignancy, severe comorbidity, contraindication to general anesthesia, active untreated infection, noncorrectable coagulopathy, pregnancy, or those requiring emergency surgery are unlikely to benefit or are excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter, single-arm pilot enrolling 10 adults with newly diagnosed operable stomach or gastro-esophageal junction cancer to undergo robotic radical gastrectomy using the Cornerstone Sentire Surgical System C1000 Ultra with a patient-side single (5th) arm. Surgeons will perform elective proximal, distal, or total gastrectomy with the device, and the study will record technical success of the procedures and perioperative complications. Outcomes include the technical success rate, incidence of intra- and postoperative complications, and feasibility signals to guide larger studies. Patients will be recruited at Prince of Wales Hospital (The Chinese University of Hong Kong) and Fujita Health University Hospital (Nagoya, Japan).
Why it matters
Potential benefit: If successful, the device could improve precision and ergonomics in minimally invasive gastrectomy and potentially reduce surgical trauma and complications.
How similar studies have gone: Robotic gastrectomy using established systems has shown benefits compared with open surgery, but the Cornerstone Sentire system with a patient-side 5th arm is a novel platform and this configuration is largely untested in humans.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-75 * Body mass index \<35 kg/m2 * Newly diagnosed tumors of the stomach / gastro-esophageal junction, scheduled to undergo elective gastrectomy (Proximal gastrectomy, distal gastrectomy, total gastrectomy) * Willingness to participate as demonstrated by giving informed consent Exclusion Criteria: * Previous abdominal surgery precluding performance of MIS gastrectomy * Contraindication to general anesthesia * Severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic intervention * Untreated active infection * Noncorrectable coagulopathy * Presence of another malignancy or distant metastasis * Emergency surgery * Vulnerable population (e.g., mentally disabled, pregnancy)
Where it's running
-
The Chinese University of Hong Kong
Hong Kong, Hong Kong Recruiting -
Fujita Health University Hospital
Nagoya, Japan Not yet recruiting
Study contacts
- Study coordinator: Hon Chi Yip, MBChB, FRCSEd (General)
- Email: hcyip@surgery.cuhk.edu.hk
- Phone: +852 35052956
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
IM-1617 in people with advanced solid cancers
A first-in-human study will test IM-1617 to see if it is safe and helps treat solid tumors that have spread or cannot be removed.
-
AI language tools to help tumor care teams write MDT reports
We will test whether AI language tools can help junior cancer doctors write MDT diagnosis and treatment reports more accurately and faster.
-
First-in-human testing of 3H-10000 for unresectable or metastatic lung and stomach cancers
This trial will test whether the experimental drug 3H-10000 is safe and helps adults with unresectable or metastatic lung or stomach cancer.
-
Ivonescimab plus FOLFOX for advanced HER2-negative stomach and gastroesophageal junction adenocarcinoma
This study tests whether adding ivonescimab to standard FOLFOX chemotherapy helps people with advanced, HER2-negative stomach or gastroesophageal junction adenocarcinoma as first-line treatment.
-
18F-G1 PET/CT to see early immunotherapy response in solid tumors and blood cancers
We are testing if the 18F-G1 PET/CT scan can help tell early on whether people with solid tumors or blood cancers will respond to immunotherapy.
-
Treatment of advanced cancers using CEA-targeted CAR-T cells
This study is testing a new type of CAR-T cell treatment for people with advanced cancers that have a specific marker, to see if it is safe and how well it works for those who haven't had success with other treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.